Genedrive Stock

Genedrive PEG

The PEG Ratio (Price/Earnings-to-Growth) of Genedrive (GDR.L) as of Aug 8, 2026 is -1.67.

PEG

-1.67

Last updated:

PEG Ratio (Price/Earnings-to-Growth) of Genedrive is 2026 -1.67 . PEG Ratio (Price/Earnings-to-Growth) of Genedrive was 2025 0.00 . It decreases by % lower compared to the previous year.
Access this data via the Eulerpool API

Genedrive Stock analysis

What does Genedrive do? Genedrive PLC is a biomedical company based in Manchester, United Kingdom, specializing in the development of innovative diagnostic tests for infectious diseases and cancer. The company was founded in 2007 under the name Epistem Limited and went public in 2013. The business model of Genedrive involves developing and distributing innovative molecular diagnostic tests for diseases worldwide. The company's main goal is to change the way infectious diseases and cancer are diagnosed and treated by offering rapid, accurate, and cost-effective tests. The company has two main divisions: Genprobe and Instruments. Under Genprobe, various in vitro diagnostic tests for infectious diseases and diseases of the human immune system, including tuberculosis, hepatitis C, hepatitis B, HIV, and others, are offered. Under Instruments, Genedrive offers PCR instruments used for analyzing samples for DNA and RNA sequences. Some of Genedrive's key products include: - Genedrive HCV-ID Testkit: A test kit for identifying and quantifying hepatitis C viruses (HCV) in human blood samples. The test provides results within 90 minutes and has high accuracy. - Genedrive MT-RNR1 Testkit: A test kit for the rapid diagnosis of tuberculosis (TB), one of the most common infectious diseases worldwide. The test utilizes PCR technology and provides results within 90 minutes. - Genedrive Genedrive 96: An instrument for simultaneous analysis of up to 96 PCR samples. The system offers high accuracy and precision in analyzing RNA and DNA sequences. The company collaborates closely with leading research institutions and health organizations worldwide to improve its products and develop new tests. Genedrive has formed partnerships with the British government, the US Department of Defense, and other institutions. In recent years, the company has made significant progress in developing new diagnostic tests for infectious diseases and cancer. For example, Genedrive recently signed an agreement with the Foundation for Innovative New Diagnostics (FIND) to develop a molecular test for the Ebola virus. The company also has a pipeline of projects, including tests for COVID-19 and antibiotic resistance. Despite Genedrive's success, the company remains committed to innovation and research in order to transform the diagnostics industry and improve the health of people worldwide. Genedrive is expected to continue playing an important role in the fight against infectious diseases and cancer in the future. Genedrive is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Genedrive stock

PEG Ratio (Price/Earnings-to-Growth) of Genedrive is -1.67 in 2026.

On Eulerpool you can find the complete historical development of PEG Ratio (Price/Earnings-to-Growth) Genedrive since 2006 – with annual values, charts, and detailed analysis.

The PEG ratio adjusts the P/E ratio by the expected earnings growth rate. A PEG below 1 may indicate an undervalued stock relative to its growth potential.

PEG = P/E Ratio / Expected Annual EPS Growth Rate

To evaluate PEG Ratio (Price/Earnings-to-Growth)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for PEG Ratio (Price/Earnings-to-Growth).

A 'good' varies by industry and company stage. On Eulerpool, you can compare PEG Ratio (Price/Earnings-to-Growth)'s Genedrive with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

Valuation — Genedrive

All Key Metrics — Genedrive